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Introduction: Chagas’ disease is the leading cause of infectious myocarditis worldwide. This 
infection caused by Trypanosoma cruzi is usually life-long and asymptomatic; however, the third 
part of infected people can develop severe or even fatal cardiomyopathy. As the parasitemia in 
the chronic phase is both low-grade and intermittent, T. cruzi infection is principally detected by 
serology, although this method has sensitivity and specificity limitations.
Objective: To determine the level of agreement between serologic and molecular tests in 
658 voluntary blood donors from six provinces in the Colombian department of Santander. 
Materials and methods: We evaluated an array of diagnostic technologies by cross-section 
sampling performing a serological double diagnostic test for T. cruzi antibody detection 
(Chagas III ELISA™, BiosChile Group, and ARCHITECT Chagas CMIA™, Abbott), and DNA 
detection by polymerase chain reaction (PCR). We collected the demographic, clinical, and 
epidemiological information of participants. The sample size was calculated using Epidat™ 
and the statistical analysis was done with Stata 12.1™. 
Results: PCR was six times more sensitive in detecting T. cruzi infection than ELISA/CMIA 
with prevalence values of 1.8% (12/658) and 0.3% (2/658), respectively, and kappa=0.28 
(95%CI: -0.03 - 0.59). In contrast, serology showed a sensitivity of 16.7% (95%CI: 2.09 - 
48.4) and a specificity of 100% (95%CI: 99.4 - 100). All seropositive samples were found to 
be positive by PCR. 
Conclusions: The implementation of PCR as a complementary method for screening 
donors could reduce the probability of false negative and the consequent risk of 
transfusional-transmission of Chagas’ disease, especially in endemic regions. 
Keywords: Trypanosoma cruzi; Chagas disease; blood donors; serology; polymerase chain 
reaction.
Desacuerdo entre la PCR y la serología en el diagnóstico de la infección por 
Trypanosoma cruzi en donantes de una región endémica de Colombia
Introducción. La enfermedad de Chagas constituye la principal causa de miocarditis 
infecciosa en el mundo. Causada por Trypanosoma cruzi, la infección puede persistir toda 
la vida de manera asintomática y silenciosa, pero un tercio de los infectados desarrolla 
cardiomiopatía grave. Debido a que la parasitemia en la fase crónica es baja e intermitente, 
el diagnóstico se hace principalmente mediante la detección de anticuerpos (serología), 
método que tiene limitaciones de sensibilidad y especificidad.
Objetivo. Determinar la concordancia entre el diagnóstico serológico y molecular de T. cruzi 
en 658 donantes voluntarios de sangre del departamento de Santander, Colombia.
Materiales y métodos. Se hizo un estudio de evaluación de tecnologías diagnósticas 
con muestreo transversal, utilizando un doble diagnóstico serológico para la detección de 
anticuerpos anti-T. cruzi (Chagas III ELISA™, BiosChile Group, y ARCHITECT Chagas 
CMIA™, Abbott) y la de ADN por PCR. Se recolectó la información demográfica, clínica y 
epidemiológica de los participantes. El tamaño de la muestra se estimó utilizando Epidat™ 
y el análisis estadístico se hizo mediante Stata 12.1™.
Resultados. La sensibilidad de la PCR fue seis veces mayor que la de las pruebas de 
ELISA/CMIA, con prevalencias de 1,8 % (12/658) y 0,3 % (2/658), respectivamente, y 
kappa de 0,28 (IC95% -0,03 - 0,59). La sensibilidad serológica fue de 16,7 % (IC95% 2,09 
- 48,4) y la especificidad de 100 % (IC95% 99,4 - 100). Todas las muestras seropositivas 
fueron positivas también en la PCR.
Conclusiones. El uso de la PCR como método complementario para la tamización de 
donantes podría reducir el riesgo de falsos negativos y disminuir los casos de transmisión 
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Chagas’ disease is an infection caused by the hemoflagellate protozoan 
Trypanosoma cruzi and it is considered one of the most significant neglected 
tropical diseases affecting 6 to 7 million individuals worldwide (1). In Latin 
America, this infection is reported as endemic in 21 countries leading to 
approximately 12,500 deaths per year and economic losses estimated at 
around USD$ 1.2 billion (almost five times greater than the regional malaria 
burden) (2,3). In the last few decades, this disease has become a global 
phenomenon, principally led by large-scale human migrations from endemic 
and rural regions to urban and non-endemic countries (Europe, USA, Canada, 
and Japan, among others) (4). In Colombia, the prevalence of T. cruzi infection 
has been estimated at 700,000 to 1,200,000 cases with the country’s eastern 
departments being the most affected: Arauca (21.1%), Casanare (10%), and 
Santander (6.3%) (5).
Trypanosoma cruzi infection commonly exhibits a prolonged asymptomatic 
course (indeterminate phase), which can progress to severe chronic heart 
and digestive system disease or death in approximately 30% of cases. These 
clinical characteristics can delay the etiological diagnosis making it difficult to 
determine the real epidemiological impact of the infection. 
Current Chagas’ disease treatments are mainly aimed at the control of 
acute infection with good results in terms of parasite clearance. However, 
for the chronic phase, there is still no treatment to cure the infection 
or to prevent its progression (6). In the long term, the treatment in the 
indeterminate disease is most cost-effective than the therapy in the chronic 
phase when moderate to severe cardiomyopathy is established (7). In these 
cases, benznidazole decreases parasitic load and reduces heart injury 
(7). Consequently, it is important to rethink the epidemiological control 
measures for Chagas’ disease and to develop and implement better methods 
for the detection of the etiological agent improving, therefore, the timely 
diagnosis and treatment of infected people before tissue damage or parasite 
transmission occurs (8).
As parasitemia is both low-grade and intermittent in the chronic phase 
of the infection, the diagnosis is based on the detection of anti-T. cruzi by 
serological methods (9), but currently, there is not an ideal serological test 
or gold standard (10). However, the systematic screening of asymptomatic 
individuals (such as blood donors) is performed via the indirect detection 
of specific antibodies generated against the parasite in serum samples 
processed by methods such as ELISA and CMIA. Nevertheless, sensitivity 
and specificity limitations have been reported for this method in endemic 
regions where seronegativity has been described in patients diagnosed 
by direct methods and clinical findings (serosilent patients) (11-14). These 
disagreements between direct and serological techniques represent a serious 
risk of contagion, especially among recipients of blood or its components. 
Molecular detection of the parasite’s nuclear or kinetoplast DNA by PCR 
has been described as highly sensitive and specific and it is especially useful 
in the indeterminate and chronic phases of the infection. Unfortunately, the 
optimization and standardization of these methods have been difficult, with 
disagreements in results commonly found in comparison studies (15-17), and 
there is no commercial PCR assay for Chagas’ disease available yet.
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In comparative studies in blood donors, discordant results in serological 
and conventional, or even real-time PCR tests, have been reported in the 
third part of infected individuals (8,15,18). In enzootic infections as Chagas’ 
disease, the seroconversion phenomena can occur in endemic areas 
associated with evolution adaptation mechanisms for parasite tolerance 
through parasitemia control or the absence of a fully-developed immune 
response, which is not necessarily equivalent to parasite clearance (8,19,20). 
Consequently, the parasitological cure could be established based on negative 
results in specific molecular tests more than by negative seroconversion (8).
In this context, we conducted a comparative study of the results obtained 
with two commercial serological (ELISA and CMIA) and molecular (in-house 
PCR) tests performed in 658 voluntary blood donors from the department of 
Santander, Colombia, an endemic region for Chagas’ disease. The results 
of both assays were then compared showing a better performance of the 
molecular method in terms of sensitivity.
Materials and methods
Materials
We used a QIAamp DNA Blood MiniKit™ (Qiagen) for whole DNA extraction 
from blood. GoTaq Flexi™, dNTPs Mix™, 5X Buffer GoTaq Flexi™, and 25 
mM of MgCl were purchased from Promega. We also used a Mastercycler 
Nexus™ (Eppendorf), a Wide Mini-Sub Cell GT Cell Horizontal Electrophoresis 
Chamber™, and a NanoDrop ND-1000 UV-VIS Spectrophotometer™ 
(Thermo Fisher Scientific). The PowerPac HC™ and the Gel Doc XR +Gel 
Documentation System™ were acquired from Bio-Rad. The Gene Ruler 1 kb 
and the 6X DNA Loading Dye were purchased from Thermo Fisher Scientific. 
Agarose and SYBR Safe DNA Gel Stain™ were purchased from Invitrogen Life 
Technologies. All the reagents and the water used were ultrapure.
Study design
We evaluated the diagnostic technologies by cross-sectional sampling 
performing a serological double diagnostic for T. cruzi antibody detection and 
DNA detection by PCR. Blood samples were prospectively collected from 658 
voluntary donors who had participated in blood donation campaigns organized 
by a blood bank from a third-level hospital in Santander. 
All the volunteers completed two self-reported questionnaires: one for 
blood bank-donor selection and the other to collect specific information 
for the study. To prevent unintentional double registrations, we excluded 
individuals previously sampled in the study. Relevant demographic, clinical, 
and epidemiological information was also collected. Consecutive sampling 
was performed over approximately twelve months (June, 2013, to May, 2014) 
until reaching the previously-determined sample size, which was calculated 
using Epidat 4.1™ software taking into consideration the reported prevalence 
for T. cruzi infection in the blood bank (5%) with 95% confidence level and 5% 
minimum precision.
 Inclusion and exclusion criteria
We selected individuals who signed the informed consent, complied 
with the Colombian blood donor standards, and provided all the specific 
information required for the study variables.
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Blood samples
Whole blood and serum samples for molecular and serological tests 
were collected on the same day by phlebotomy in 5 ml Vacutainer™ sterile 
tubes with EDTA or without anticoagulant, respectively. Serum samples were 
separated within two hours of collection and kept at -20°C until serological 
processing. EDTA-supplemented blood samples were preserved at 4°C and 
protected from light until DNA extraction. The serology and DNA extraction 
procedures were completed within 15 days of collection.
 DNA extraction
DNA extraction from EDTA-supplemented blood samples was performed 
using a QIAmp DNA Blood Mini Kit™ (QIAGEN) following the manufacturers’ 
protocol slightly modified. Briefly, 200 µl of blood were washed twice with 
STE solution (100 mM NaCl; 10 mM Tris-Cl, pH 8.0; 1 mM EDTA) on the 
sample-equilibrated column to reduce the ionic strength and to optimize DNA 
extraction. The quality of the extracted DNA was confirmed using 1% agarose 
electrophoresis and its concentration was determined on a NanoDrop ND-
1000 UV-VIS Spectrophotometer™ (Thermo Fisher Scientific), and quantified 
with the NanoDrop 2000/2000c Spectrophotometer Software™ (Thermo 
Fisher Scientific). As controls, we used 300 μl of each whole blood sample on 
Whatman No. 3 filter paper stored in 1.5 ml sterile plastic tubes at -20°C. 
Polymerase chain reaction (PCR)
PCR assays were performed using the forward TckDNA121F 
(5´-AAATAATGTACGGGGGAGATGCATGA-3) and the reverse TckDNA122R 
(5´-GGTTCGATTGGGGTTGGTGTAATATA-3´) primer sequences described by 
Sturm, et al. (21). These oligonucleotides were designed based on conserved 
regions of the T. cruzi 9813 strain and V101 clone kinetoplast DNA (GenBank 
accession number 311875422) and synthesized by Invitrogen Life Technologies. 
For the PCR, we used total DNA and control samples from patients 
as templates. We optimized the PCR reagent concentrations and running 
conditions based on amplicon efficiency and specificity parameters. The 
positive DNA controls used for the PCR assays were: a) genomic material 
extracted from an axenic LIT culture of T. cruzi I (TcI) SYLVIO-X10 strain 
epimastigotes, and b) total DNA isolated from EDTA-blood samples obtained 
from clinically confirmed patients with chagasic cardiomyopathy. All samples 
were processed in duplicate in two independent experiments and all positive 
PCR samples were confirmed in triplicate. 
The quality, sensitivity, and specificity of the DNA amplification were assessed 
using 1.5% DNA agarose electrophoresis assays stained with 1X SYBR Safe™ 
(Invitrogen Life Technologies), then visualized using a 302 nm UV transilluminator, 
and documented with a Gel Doc XR+ Gel Documentation System™ (BioRad).
Anti-T. cruzi antibodies
We screened the serum samples for anti-T. cruzi antibodies using a 
Chagas III ELISA Kit™ (BiosChile Group) and retested using an ARCHITECT 
Chagas CMIA Kit™ (Abbott) following the manufacturer’s instructions. 
Samples with results above the cutoff value in both ELISA and CMIA tests 
were considered positive and confirmed by Western Blot. The absorbance 
cutoff values were below 0.3 in all the analyses performed. Sera from patients 
with chronic chagasic cardiomyopathy were utilized as positive controls.
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Statistical analysis
The personal, clinical, and epidemiological data of the donors, as well as 
their serological and PCR results, were recorded in a database with the Epidata 
3.1. software. Frequency distribution, central tendency, and dispersion statistics 
were calculated for the quantitative variables and proportions for the qualitative 
variables. The association between the independent variables and the infection 
and the normality of the continuous data were evaluated using the chi-square 
and Shapiro Wilk tests, respectively. The agreement between ELISA/CMIA 
and PCR was calculated by means of the kappa coefficient. The sensitivity, 
specificity, positive predictive value (PPV), and negative predictive value (NPV) 
of the serological tests were calculated taking the PCR as the defined reference 
test. All statistical analyses were carried out using Stata 12.1™.
 Ethical considerations
The study was approved by the Ethics and Research Committee at 
Universidad de Santander and by the Ethics Committee of the hospital to 
which the blood bank is affiliated and conducted according to the current 
Colombian legislation (Resolution 8430 of 1993) and the Helsinki Declaration. 
All participants signed an informed consent form. 
To guarantee confidential data handling, information was coded. All 
assays using donor samples were performed in accordance with defined 
quality control standards. Blood donors identified during screening as T. cruzi 
seropositive were referred for medical attention and follow-up testing including 
hemoculture and Western Blot.
Results
Study population 
The main demographic characteristics of the study population (place 
of residence, sex, age, and occupation) are shown in table 1. The study 
population (658 voluntary donors) was composed mainly of young people 
(50% aged 18 to 24, average age: 28.9 years ± 10.1 SD), males (59.4%, 
n=391), O blood type (61.2%, n=403), Rh+ (60.5%, n=399), students (56.5%, 
n=372), and residents in several Santander municipalities (93.3%, n=614) 
75% of them located in Chagas’ disease-endemic areas. 
The provinces of Guanentá (n=380), Comunera (n=164), and Yariguíes 
(n=28) provided 86.9% (n=572) of the collected samples, mainly from the 
towns of San Gil (n=338), Socorro (n=152), and Barrancabermeja (n=27), 
correspondingly (figure 1). The remaining donors (3.3% non-residents) 
came from other Colombian departments also endemic for Chagas’ disease 
according to the National Public Health Surveillance System (6): 1.4% (n=9) 
from Boyacá; 1.1% (n=7) from Bolívar; 0.3% (n=2) from Magdalena; 0.3% 
(n=2) from Cesar; 0.2% (n=1) from Casanare, and 0.2% (n=1) from Sucre. 
The residence data of 17 donors were missing. 
Risk factors were only reported by 7.1% (n=47) of the participants (table 2). 
Only 40.7% (n=268) had donated blood previously and a very low percentage 
(0.6%, n=4) had been bitten by a triatomine bug at some point in their lives.
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1 Endemic regions for leishmaniasis, dengue, malaria or yellow fever  
* p<0.05: statistically significant
Missing data (n=17); non-endemic departments (n=5
Table 1. Demographic characteristics of the study population 
Figure 1. Colombian map of sample collection sites and zoom into Santander department and its provinces. )
Table 2. Association between risk factors for transfusion-transmissible 
infections and PCR positive results for Trypanosoma cruzi 
n: Number; F: Female; M: Male
* 31 Missing data
¹ Unemployed: Retired and housewife people
2 Other Colombian departments: Endemic [Boyacá 1.4% (n=9), Bolívar 1.1% (n=7), Magdalena 0.3% (n=2); Cesar 0.3% (n=2); Casanare 







n % n % n % n % n %
Santander 614 93.3 257 39.0 357 54.2 29.4 ± 10.3 359 54.5 233 35.4 10 1.5
Comunera 164 24.9 75 11.3 89 13.5 26.0 ± 7.0 127 19.3 33 5.0   2 0.3
García Rovira 8 1.2 - - 8 1.2 24.2 ± 2.8 8 1.2 - - - -
Guanentá 380 57.7 168 25.5 212 32.2 31.7 ± 11.2 196 29.8 166 25.2   8 1.2
Metropolitana 21 3.2 6 0.9 15 2.3 25.7 ± 6.7 9 1.4 12 1.8 - -
Soto Norte 1 0.2 1 0.2 - - 22.0 - 1 0.2 - - - -
Vélez 1 0.2 - - 1 0.2 21.0 - - - 1 0.2 - -
Yariguíes 28 4.3 4 0.6 24 3.6 22.0 ± 1.4 15 2.3 13 2.0 - -
Not reported 11 1.7 3 0.5 8 1.2 29.1 ± 13.8 3 0.5 8 1.2 - -
Other departments2 - 27 4.1 6 0.9 21 3.2 22.7 ± 1.7 13 2.0 12 1.8 - -
Missing data - 17 2.6 4 0.6 13 2.0 - - - - - - - -
658 100 267 40.6 391 59.4 28.9 ± 10.1 372 56.5 245 37.2 10 1.5














Variable n=658 % PCR (+)/(-) p value*
Tattoo <12 months
Travel to endemic regions1 <6 months
Transfusion <12 months
Biological accident <6 months
Hallucinogenic drug use <12 months
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 DNA isolation and amplification
For PCR assays, total DNA was isolated from whole blood samples 
and concentrations between 40 and 70 ng/µl were obtained and used as 
templates. The amplification assays were performed using the oligonucleotide 
pair described by Sturm, et al. (21). To increase the 330 bp T. cruzi-
kDNA amplicon production and the specificity of the test, the reagent 
concentrations and cycling parameters used were optimized as indicated in 
the supplementary material (table S1). The sensitivity of the optimized PCR 
was estimated at 12.5ng/µl of DNA (equivalent to 1 cell/µl) using total DNA 
samples isolated from T. cruzi cultures as templates at various concentrations. 
Non-target-size bands were generated employing T. theleri, T. evansi, and 
Leishmania amazonensis genomic material as DNA templates to confirm a 
100% specificity for the optimized test (figure 2A).
 Serological vs molecular test
We found 0.3% (n=2) of samples positive for T. cruzi antibodies in serum 
with both serological methods (Chagas III ELISA Kit™ from BiosChile 
Group and ARCHITECT Chagas CMIA Kit™ from Abbott). Conversely, in the 
molecular analysis, we found a total of 12 samples (1.8%) (figure 2B). We 
did not find false positives as all the positive serological results (n=2) also 
exhibited the specific amplicon band by PCR thus allowing us to estimate a 
100% specificity for the serological techniques used. According to the PCR 
results, a 1.8% (n=12) T. cruzi infection prevalence was calculated for the 
study population. Using the kappa coefficient, the agreement between the 
serological and molecular results was calculated at 0.28 (95%CI: -0.03 - 0.59) 
and the following serology parameters were estimated using the molecular 
assay as the defined reference test: Sensitivity, 16.7% (95%CI: 2.09 - 48.4); 
specificity, 100% (95%CI: 99.4 - 100); PPV, 100% (95%CI: 15.8 - 100), and 
NPV, 98.5% (95%CI: 97.2 - 99.3) (table 3).
Figure 2. PCR products in 1.5% agarose electrophoresis gel. A. Control DNA samples. B. Positive 







MW PC NC NC L.a T.t T.e





MW: Molecular Weight Gene Ruler 1Kb DNA Ladder; PC: Positive control (Trypanosoma cruzi culture 
total DNA extraction); NC: Negative control;: L.a: Leishmania amazonesis. T.t: Trypanosoma teilheri; 
T.e: Trypanosoma evansi
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To determine possible associations, the twelve donors who tested positive 
by either PCR or serology were characterized using parameters such as their 
place of residence, sex, occupation, and relevant epidemiologic backgrounds 
(triatomine bite or previous donation) (table 2). It is noteworthy that 83% 
(10/12) of the individuals who tested positive for T. cruzi infection by PCR 
came from the province of Guanentá (San Gil), 75% (9/12) were male, and 
33% (4/12) had previously donated blood. One of the two individuals who 
tested positive by both serology and PCR assays (sample 78) reported having 
previously suffered a triatomine bite (table 2). 
Discussion
In endemic areas of many Latin American countries, T. cruzi is primarily 
transmitted by contact with the feces of infected blood-sucking triatomine bugs 
(vector-borne). However, transmission by transfusion remains significant, 
principally due to the dispersal of the infection beyond the geographical 
borders of insect vectors, which alters the infection’s epidemiological dynamics 
(4). Control efforts in the region have been centered on vector control and 
the implementation of protocols and regulations for compulsory blood donor 
screening. The prevalence of T. cruzi infection among blood bank donors has 
shown a great variation, with rates varying between 1.3% and 51% (22). In 
Colombia, the seroprevalence in blood donors has been reported between 
0.09% and 2.1% depending significantly on the region studied (23-28), with an 
estimated 5% in the nation’s general population (27). In Santander, the T. cruzi 
infection rate for voluntary blood donors has been reported at around 0.53% (28).
Currently, blood safety depends primarily on the sensitivity of the laboratory 
screening tests, as well as on the implementation of progressively more 
stringent donor eligibility criteria. However, due to the largely asymptomatic 
course of T. cruzi infection and its characteristic low parasitemia, in its late 
stages, the diagnosis is traditionally carried out using two or more serologic 
tests for specific IgG antibody detection (9). In blood bank screening, the most 
commonly-used methods are those based on enzyme-linked immunosorbent 
assays (ELISA) and chemiluminescent microparticle immunoassays (CMIA), 
with more complex techniques, such as indirect immunofluorescence (IFI) and 
immunoblotting, generally being used for confirmatory purposes. Previously, 
high specificity and sensitivity levels (up to 95% of IFI standards) have been 
reported for ELISA and CMIA assays, as well as a high reproducibility of 
ELISA, IFI, and indirect hemagglutination (IHA) (29,30), but they also exhibit 
limitations that should be considered and analyzed through comparative 
studies with modern complementary techniques (29). For example, the false 
seropositive results reported in these tests have been explained by the cross-
reactivity with other hemoflagelate protozoa such as Leishmania spp. or 
Trypanosoma rangeli (29,31). Additionally, and most preoccupying, multiple 
studies have reported seronegativity in patients who are symptomatic for 
*Kappa coefficient: 0.28 (95%IC: -0.03-0.59); sensitivity: 16.7% (95%CI: 2.09-48.4); specificity: 
100% (95%CI: 99.4-100); positive predictive value (PPV) 100% (95%CI: 15.8-100), and 
negative predictive value (NPV) 98.5% (95%CI: 97.2-99.3)
Table 3. Sensitivity, specificity, predictive values and concordance of 
serological tests as compared to PCR for the diagnosis of Trypanosoma 
cruzi infection in blood donors from a Colombian endemic region 
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Chagas’ disease and exhibit molecular evidence of T. cruzi infection (i. e. who 
are PCR-positive) (12,31,32).
Here we conducted a comparative study of two methods for serological 
screening of specific T. cruzi antibodies (Chagas III ELISA Kit™ from 
BiosChile Group and ARCHITECT Chagas CMIA Kit™ from Abbott) and a 
molecular technique using the in-house PCR protocol previously described by 
Sturm, et al. (21). The tests were applied to 658 voluntary blood donors from 
a Chagas’ disease-endemic region (Santander, Colombia) with a reported 
6.3% T. cruzi infection prevalence (5) and great diversity in domestic and wild 
triatomine insects (11 different species of which seven are involved in Chagas’ 
disease transmission) (5,33).
Our results showed that the molecular method was six times more 
sensitive than the ELISA and CMIA assays at detecting T. cruzi infection 
in blood samples. These results are in agreement with previous studies 
documenting a better performance for molecular methods in terms of 
sensitivity and specificity, especially for parasite detection in blood samples 
from chronic patients and cases of doubtful serological tests (8,11-14,18,31). 
Thus, in patients with cardiac (12) and/or digestive abnormalities (13), which 
are characteristic of chagasic infection with low parasitemia, PCR appeared 
to be an efficient method for T. cruzi DNA detection even for doubtful (8,11) or 
serologically negative cases (8,12,13).
Comparative studies of serological results and molecular PCR test 
performed in a cross-sectional blood donor cohort evidenced low antibody 
levels or discordant test results in one third of the seropositive samples 
(8,18). These results were explained by parasite tissue sequestration after the 
resolution of acute infection leading to a low-grade and intermittent parasitemia 
in indeterminate and chronic infection stages (8,18-20). These phenomena can 
be also accompanied by a low antigenic stimulus with a resulting low antibody 
production or even seroconversion (19-20). The association of antibody 
levels with peripheral parasitemia was previously described in blood donor 
studies (8,15), parameters that were also correlated with the severity of the 
chagasic cardiomyopathy (8). These authors concluded that in endemic areas 
a minor proportion of the infected individuals are able to control the circulating 
parasite in the blood (8), but does not necessarily represent its elimination. 
Consequently, the absence of reliable biomarkers to identify the parasite 
persistence is a major obstacle to understand the natural history of chagasic 
cardiomyopathy and determine the true impact of the disease.
The performance of the molecular method can be explained by the fact 
that PCR is based on direct detection of parasite DNA while immunological 
tests are strongly dependent on the patient’s immune status and the time 
since infection. They also rely heavily on the technical conditions under 
which the assays are performed (for example, antigen, parasite lineage, 
or developmental stage, among others) (31,32). Therefore, despite chronic 
infection, some patients are unable to develop an antibody response 
detectable by conventional serology. This phenomenon could be more 
common than expected as revealed by previous reports in endemic nations 
such as Argentina, Bolivia, Venezuela, and Brazil (12,13,33). Some of its 
possible causes include: a) window-phase or very low antibody titers in the 
early stage of infection (34); b) inability of some T. cruzi strains to induce 
specific antibody production (35); c) HIV co-infection causing decreased 
antigen presentation due to virus tropism on CD4+ T-, dendritic, and natural 
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killer cells, and the consequent impairment of their antibody secretion (36); d) 
non-responder phenomenon or persistent antibody-negative (immunosilent) 
carriers who are unable to produce a detectable humoral response and 
present appropriate antigens (possibly associated with CD4+ and CD8+ T-cell 
depletion due to the affinity of the thymus as a T. cruzi-infection target), as well 
as the reduction of IL-2 (a pivotal cytokine in cellular memory immunity and 
antigen recognition) (34,35), and e) procedural testing errors.
Currently, PCR protocols using different targets such as repeated satellite 
sequences (11), Tc24 flagella proteins 3´end ORF (37), or kinetoplast DNA 
(21) have been described. The PCR described by Sturm, et al. (21), uses 
a specific primer pair for the amplification of a 330 bp fragment from kDNA 
minicircles resulting in a highly sensitive (70% to 100%) and specific (96.5% 
to 100%) method due to the high copy-number of the mitochondrial genome 
(10,000 to 30,000 minicircles and their respective four copies in the variable 
region). Additionally, this protocol was also reported to exhibit specificity of 
100% compared to other kinetoplastid genera (Crithidia luciliae, Leptomonas 
collosoma, Herpetomonas mariadeanei, Endotrypanum spp., Blastocrithidia 
culicis, Leishmania tarentolae, and T. rangeli) (21), which explains why we 
selected and optimized the method to use it as the molecular test. The 
modified PCR results in an increase in sensitivity and specificity rates.
In the present study, all positive samples by serology (2/658) were also 
positive by PCR (two true positive results), however, 10 samples were only 
found positive using the molecular assay (10 false negatives by serology). 
Given that four of the PCR-positive donors had previously donated blood, 
an apparent epidemiological risk is evident for transfusion-transmission 
associated with possible false negatives from serology.
In the correlation analysis of T. cruzi PCR-positive donors and the 
independent variables (table 2), the triatomine bite was the only variable that 
showed a statistically significant association (p<0.001); this risk factor was 
reported by 33.3% (4/12) of the PCR-positive individuals and 10/12 (83.3%) of 
these positive donors were residents in Guanentá, a highly endemic area for 
Chagas’ disease (table 1).
Regarding serological methods, 96% sensitivity and 99% specificity levels 
have been estimated for screening ELISA assays (38). Specifically for the 
Chagas III ELISA kit from the BiosChile Group an 82% to 99% specificity and 
a 99% sensitivity have been reported (39,40), and the test has also shown 
an excellent concordance with other ELISA tests, such as the Chagas test 
IIC V.1 (Research Institute in Health Sciences at Universidad Nacional de 
Asunción, Paraguay) and the Chagatest ELISA (Wiener) (40), with a kappa 
index of 0.92. However, in aboriginal communities in the Venezuelan States 
of Bolívar and Delta Amacuro, the ELISA Chagas III (BiosChile) method 
had a poor performance in detecting specific T. cruzi-IgG antibodies (41). A 
significant performance disagreement has also been reported for commercial 
ELISA results for T. cruzi antibody detection. In this regard, Guzmán-Gómez, 
et al. (42), analyzed 37 samples using five serological techniques and found 
that only one sample was positive with all techniques: one with four and nine 
with three. All samples were positive for at least two of the tests used but in a 
matrix of various combinations (42).
It is important to acknowledge that the population recruited in blood 
donor campaigns (as in this study) are demographically different from the 
conventional donors routinely attending blood banks and both of them differ 
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from the general population. Therefore, the prevalence registered in our 
study cannot be considered the Chagas’ disease prevalence in the general 
population, mainly because the volunteer participants were mostly males, 
students, young, and unemployed (table 1); besides they were in good 
health and had healthy personal habits (28). It is possible, then, that a higher 
prevalence would be found in the general population in Santander from all age 
and sex groups, as well as normal occupational diversity.
However, our purposes were first, to compare the diagnostic utility of 
ELISA/CMIA and PCR techniques for Chagas’ disease diagnosis; second, 
to determine the existence of a possible serosilent phenomenon in blood 
donors from Santander municipalities, and third, to emphasize the need to 
rethink progressively more restrictive donor eligibility criteria and increasingly 
sensitive blood donor screening methods like PCR. The implementation of a 
PCR test, as described herein, could be used as a complementary method 
for screening blood donors thus reducing the risk of false-negative results and 
Chagas’ disease transmission by transfusion, especially in endemic regions 
such as the department of Santander in Colombia.
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Table S1. PCR parameters for Trypanosoma cruzi kDNA amplification 
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5 minutes at 94°C
34X
40 seconds at 94°C
40 seconds at 55ºC
50 seconds at 72ºC
10 minutes at 72°C
2 minutes at 94°C
34X
1 minute at 93°C;
1 minutes at 37ºC
1-2 minutes at 70ºC
1-2 minutes at 70°C
NR: Not reported
